Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
31
03
2020
revised:
30
06
2020
accepted:
02
07
2020
entrez:
18
7
2022
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Understanding how patient-reported quality of life (QoL) and socioeconomic status (SES) relate to survival of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) may improve prognostic information sharing. This study explores associations among QoL, SES, and survival through administration of the Euro-QoL 5-Dimension, 3-level and Functional Assessment of Cancer Therapy-Leukemia and financial impact questionnaires to 138 adult participants with newly diagnosed AML or MDS in a longitudinal, pan-Canadian study. Cox regression and lasso variable selection models were used to explore associations among QoL, SES, and established predictors of survival. Secondary outcomes were changes in QoL, performance of the QoL instruments, and lost income. We found that higher QoL and SES were positively associated with survival. The Lasso model selected the visual analog scale of the EQ-5D-3L as the most important predictor among all other variables (
Identifiants
pubmed: 35847696
doi: 10.1002/jha2.62
pii: JHA262
pmc: PMC9175748
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-78Informations de copyright
© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.Dr Couban, the principal investigator for the TFRI prognostic risk study, died before this publication. He was a proponent in the advancement of our understanding of patient‐relevant outcomes and was enthusiastic about sharing these results with the hematology community. His influence on the lives of patients and grace of leadership guided our collaboration.Sonya Cressman, Stephen Couban, Stuart Peacock, Donna Hogge, Mark Minden, and Aly Karsan designed the research. Sonya Cressman, Emily McPherson, Khalif Halani, and Jing Yi Weng analyzed the data. All authors participated in the interpretation of the findings and the writing of the manuscript.
Références
Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399
pubmed: 29032275
JAMA Oncol. 2017 Dec 1;3(12):1675-1682
pubmed: 28880971
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Leukemia. 2019 Oct;33(10):2393-2402
pubmed: 30923318
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Expert Rev Hematol. 2016 Sep;9(9):821-3
pubmed: 27389467
Blood. 2013 May 23;121(21):4287-94
pubmed: 23550038
Haematologica. 2011 May;96(5):696-702
pubmed: 21330327
Lancet Oncol. 2015 Nov;16(15):1506-1514
pubmed: 26404501
Biol Blood Marrow Transplant. 2019 Mar;25(3):599-605
pubmed: 30296479
Br J Haematol. 2016 Aug;174(4):526-35
pubmed: 27098559
Leuk Lymphoma. 2015 Apr;56(4):987-92
pubmed: 25012944
Ann Oncol. 2014 Apr;25(4):883-888
pubmed: 24667720
Br J Haematol. 2009 Jun;145(5):598-605
pubmed: 19344426
Oncologist. 2019 Feb;24(2):247-254
pubmed: 30139841
Eur J Haematol. 2014 Sep;93(3):198-206
pubmed: 24673368
JAMA Oncol. 2016 Dec 01;2(12):1583-1589
pubmed: 27532508
Blood. 2009 Apr 30;113(18):4179-87
pubmed: 19008455
Stat Methods Med Res. 2002 Feb;11(1):25-48
pubmed: 11923992
Leuk Res. 2016 Aug;47:142-8
pubmed: 27337292
Blood Rev. 2018 Jan;32(1):81-87
pubmed: 28888621
Bone Marrow Transplant. 2012 Nov;47(11):1385-90
pubmed: 22056642
Biol Blood Marrow Transplant. 2014 Sep;20(9):1375-81
pubmed: 24867778
PLoS One. 2012;7(2):e31115
pubmed: 22328929
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793